- Home
- CTOR vs RAPT Comparison
CTOR vs RAPT Comparison
Compare CTOR & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTOR
- RAPT
- Stock Information
- Founded
- CTOR 2021
- RAPT 2015
- Country
- CTOR United States
- RAPT United States
- Employees
- CTOR N/A
- RAPT N/A
- Industry
- CTOR
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- CTOR
- RAPT Health Care
- Exchange
- CTOR NYSE
- RAPT Nasdaq
- Market Cap
- CTOR 126.2M
- RAPT 106.8M
- IPO Year
- CTOR N/A
- RAPT 2019
- Fundamental
- Price
- CTOR $1.55
- RAPT $1.82
- Analyst Decision
- CTOR Strong Buy
- RAPT Hold
- Analyst Count
- CTOR 1
- RAPT 9
- Target Price
- CTOR $6.00
- RAPT $7.25
- AVG Volume (30 Days)
- CTOR 87.9K
- RAPT 242.3K
- Earning Date
- CTOR 08-12-2024
- RAPT 11-11-2024
- Dividend Yield
- CTOR N/A
- RAPT N/A
- EPS Growth
- CTOR N/A
- RAPT N/A
- EPS
- CTOR N/A
- RAPT N/A
- Revenue
- CTOR N/A
- RAPT N/A
- Revenue This Year
- CTOR N/A
- RAPT N/A
- Revenue Next Year
- CTOR N/A
- RAPT N/A
- P/E Ratio
- CTOR N/A
- RAPT N/A
- Revenue Growth
- CTOR N/A
- RAPT N/A
- 52 Week Low
- CTOR $1.53
- RAPT $1.77
- 52 Week High
- CTOR $49.00
- RAPT $27.35
- Technical
- Relative Strength Index (RSI)
- CTOR N/A
- RAPT 33.28
- Support Level
- CTOR N/A
- RAPT $1.77
- Resistance Level
- CTOR N/A
- RAPT $2.04
- Average True Range (ATR)
- CTOR 0.00
- RAPT 0.17
- MACD
- CTOR 0.00
- RAPT 0.01
- Stochastic Oscillator
- CTOR 0.00
- RAPT 8.21
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.